Differential indications for atypical neuroleptics. Results of a pilot study for prescriptions in German psychiatric hospitals;Differenzialindikation atypischer neuroleptika: Amisulprid, clozapin, olanzapin, quetiapin und risperidon. Ergebnisse einer pilotstudie zu verordnungsgewohnheiten in psychiatrischen versorgungskliniken der BRD

Nervenarzt

Volumn 76, Issue 3, 2005, Pages 278-284

  Gunther W ^a,d   Laux, G ^a   Trapp, W ^a   Muller N ^b   Mitznegg, N ^a   Schulze Monking H ^c   Steinberg, R ^a   Wolfersdorf, M ^a  

^a Klin F Psychiat Psychotherapie   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c St Rochus Hospital   (Germany)

^d Nervenklinik Bamberg   (Germany)

Author keywords

Atypical neuroleptics; Differential indication; Prescription habits

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; DRUG INDICATION; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; GERMANY; HALLUCINATION; HEALTH SURVEY; HUMAN; MENTAL HOSPITAL; PHYSICIAN; PILOT STUDY; PRESCRIPTION; QUESTIONNAIRE; SIDE EFFECT; SYMPTOMATOLOGY;

ANTIPSYCHOTIC AGENTS; DATA COLLECTION; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; GERMANY; HOSPITALS, PSYCHIATRIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PSYCHIATRY; SCHIZOPHRENIA;

EID: 17444404545     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-004-1795-3     Document Type: Article

References (23)

1. Allison DB, Mentore JL, Heo M (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696
2. Boyer P, Lecrubier Y, Puech A (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166:68-72
3. Burns T, Bale R (2001) Clinical advantages of amisulpride in the treatment of acute schizophrenia. J Int Med Res 29:451-466
4. Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158:765-774
5. Davis JM, Chen N, Glick ID (2003) A metaanalysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60:533-564
6. Fritze J, Schmauß M, Holsboer F (2003) Änderung der Arzneimittel-Richtlinien des Bundesausschuß der Ärzte und Krankenkassen bezüglich atypischer Neuroleptika. Stellungnahme der DGPPN und der AGNP. Nervenarzt 74:97-99
7. Gheuens J, Grebb J (1998) Comments on article by Tran and colleagues, "Double-Bind Comparison of Olanzapine versus Risperidone in the treatment of schizophrenia and other psychotic disorders". J Clin Psychopharmacol 18:176-177
8. Gründer G, Vernaleken I, Benkert O (2001) Welche Eigenschaften machen ein Atypikum "atypisch"? Nervenarzt 72:833-843
9. Ho BC, Miller D, Nopoulos P et al. (1999) A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 60:658-663
10. Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503-517
11. Kasper S, Küfferle B (1998) Comments on "Double-blind Comparison of Olanzapine versus Risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and associates. J Clin Psychopharmacol 18:353-354
12. Leucht S, Barnes TRE, Kissling W et al. (2003) Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209-1222
13. Lohse MJ, Lorenzen A, Müller-Oerlinghausen B (2004) Psychopharmaka. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2003. Springer, Berlin Heidelberg New York, S 704-749
14. McEvoy JP, Scheifler PL, Frances A (1999) The expert consensus guideline series: treatment of schizophrenia. J Clin Psychiatry 60(Suppl 11):3-80
15. Möller HJ (2000) Aktuelle Bewertung neuer/atypischer Neuroleptika. Nervenarzt 71:329-344
16. Naber D, Lambert M, Krausz M et al. (2000) Atypische Neuroleptika in der Behandlung schizophrener Patienten. Unimed, Bremen
17. Schooler NR (1998) Comments on article by Tran and colleagues, "Double-blind Comparison of Olanzapine versus Risperidone in the treatment of schizophrenia and other psychotic disorders". J Clin Psychopharmacol 18:174-175
18. Schwabe U (2004) Arzneiverordnungen 2002 im Überblick. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2003. Springer, Berlin Heidelberg New York, S 1-23
19. Schwabe U, Paffrath D (Hrsg) (2004) Arzneiverordnungsreport 2003. Springer, Berlin Heidelberg New York
20. Tohen M, Jacobs T, Grundy L et al. (2000) Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 62(Suppl 2):17-21
21. Tollefson G, Sanger T, Beasley CJ et al. (1998) A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haliperidol or placebo on anxious or depressive symptoms accompanying schizophrenia. Biol Psychiatry 43:803-810
22. Tran PV, Hamilton SH, Kuntz AJ et al. (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418
23. US Food and Drug Administation memorandum (2000) Study report of Clinical Pharmacology Protocol # 128-054